Overexpression of ErbB2 in cancer and ErbB2-targeting strategies (Q33931164)

30 July 2017

1 reference

title

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies (English)

1 reference

30 July 2017

1 reference

Yu D

1

1 reference

30 July 2017

Hung MC

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

19

1 reference

30 July 2017

issue

53

1 reference

30 July 2017

page(s)

6115-6121

1 reference

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

The neu oncogene encodes an epidermal growth factor receptor-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Antioncogenic effect of adenovirus E1A in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Medical applications of single-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Can HER2 status predict response to cancer therapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203972

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1203972

1 reference

Dimensions Publication ID

30 July 2017

1002227737

0 references

1 reference